Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Stock Information for Lunai Bioworks Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lunai Bioworks Inc Com

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split
Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery
Lunai Bioworks Strengthens European Strategy Through Restructuring
Lunai Bioworks Inc. Retains American Defense International
Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.